MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, common...
$17,154,911
Proceeds from exercise of
common stock...
$6,976,065
Proceeds from issuance of
common stock in atm...
$1,477,407
Proceeds from issuance of
short-term debt
$406,875
Net cash provided by
financing activities
$25,557,104
Canceled cashflow
$458,154
Net decrease in cash
and cash...
$962,461
Canceled cashflow
$24,594,643
Repayment of short-term
debt
$458,154
Stock-based compensation
expense
$2,227,859
Prepaid clinical trial
costs (current and...
-$540,601
Prepaid expenses and
other current assets
-$1,750
Net cash used in
operating activities
-$24,594,643
Canceled cashflow
$2,770,210
Net loss
-$19,864,902
Accrued expenses and
other current...
-$4,003,168
Accounts payable
-$3,407,773
Change in fair value of
warrant liabilities
-$89,010
Back
Back
Cash Flow
source: myfinsight.com
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)